Certified by Founder Lodge
Abcuro, Inc
United States - Newton, MA
START UP
1 Disclosed Funding Rounds $155,000,000
0 Participating Investments
-
Founded date
2015
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoin
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| August, 18 ,2023 | Series B | $155,000,000 |
BlackRock
Sanofi
RA Capital Management, L.P.
New Leaf Ventures
Mass General Brigham Ventures
Redmile Group
Samsara BioCapital
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)